AbbVie Inc. (ABBV) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
AbbVie beat Q2 2025 earnings with raised full-year guidance based on strong sales of key drugs, pipeline advancements, and a 6% dividend increase. The ~6% recent price rise and moderate upward technical momentum, despite nearing resistance, point to moderate near-term capital appreciation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High operating margins ⢠Heavy net leverage ⢠Weak liquidity ABBV generates strong operating cash and high gross/EBITDA margins but is constrained by heavy leverage, weak liquidity/negative reported equity and rich valuation multiples that elevate risk.
Price Behavior
Key Price Behavior Insights: ⢠Below last month ⢠Weakening momentum ⢠Support bounce possible Support Level: $224â225 Resistance Level: $232â236 ABBV is in a short-term downtrend below its last month average with weakening momentum (14âday RSI ~36)âwatch $224â225 as near-term support and $232â236 as key resistance after a sharp one-day drop that raises the risk of further downside.
Sentiment & News
Key News Insights: ⢠API capacity build ⢠Neuroscience growth ⢠Mixed ownership AbbVie is ramping domestic API capacity and banking on neuroscience and obesity drugs to drive midterm revenue growth while attracting mixed investor flows and experiencing near-term stock pressure.
AI Summary
AbbVie is no longer just a Humira cash machine but a leverage-funded hybrid: strong FCF and shareholder returns today increasingly hinge on successful scale-up of Skyrizi/Rinvoq and pivotal neuroscience/oncology readouts to justify current rich multiples. Action: hold and require two things before addingâclear, sustained revenue replacement evidence from Skyrizi/Rinvoq or positive pivotal readouts, and demonstrable reduction in gross leverage or consistent FCF coverage of the dividend.
Description
AbbVie Inc. is a global pharmaceutical company that discovers, develops, manufactures and markets prescription drugs across immunology, oncology, neuroscience, virology and eye care. Its portfolio includes established biologics and small-molecule therapies for conditions such as autoimmune diseases, cancer, hepatitis C, Parkinsonâs and glaucoma, alongside specialty products for endocrine and gastrointestinal disorders. The company was incorporated in 2012, is headquartered in North Chicago, Illinois, and maintains external research collaborations, including an agreement with Dragonfly Therapeutics.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 29 | Oct 6 | ABBV | AbbVie Inc. | AbbVie beat Q2 2025 earnings with raised full-year guidance based on strong sales of key drugs, pipeline advancements, and a 6% dividend increase. The ~6% recent price rise and moderate upward technical momentum, despite nearing resistance, point to moderate near-term capital appreciation potential. | Closed | +3.1% |